Poxel releases detailed Imeglimin Phase 3 results from TIMES 1 program
Category: #health  By Paroma Bhattacharya  Date: 2019-09-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Poxel releases detailed Imeglimin Phase 3 results from TIMES 1 program

Type 2 diabetes is a prevailing disease in which cells become unresponsive to insulin while gradually increasing blood sugar. With growing cases of Type 2 diabetes worldwide, pharmaceutical companies are now focusing on developing new drugs by means of novel clinical trials.

POXEL S.A., a biopharmaceutical company focused on developing novel treatments and drugs for metabolic disorders like non-alcoholic steatohepatitis (NASH) and type 2 diabetes, recently presented a detailed Phase 3 results from the TIMES (Trials of Imeglimin for Efficacy and Safety) 1 program.

According to reports, the data would be displayed in a symposium session at the 55th Annual Meeting of EASD (European Association for the Study of Diabetes), conducted in Barcelona, Spain.

Speaking on the move, Ralph DeFronzo, M.D., Professor of Medicine and Chief of the Diabetes Division at UT Health San Antonio, said that to effectively administer type 2 diabetes, treatments need to fix both the defects in insulin sensitivity and insulin secretion.

He added that Poxel’s new treatment is an innovative therapeutic approach with an exclusive mechanism of action that operates on the level of the mitochondria. Moreover, by advancing mitochondrial function, the drug has shown a rise in insulin secretion and muscle insulin sensitivity while decreasing hepatic glucose production.

Previously, the company had partnered with Sumitomo Dainippon Pharma Co., Ltd, to announce encouraging top-line Phase 3 results for Imeglimin TIMES 3 16-week, placebo-controlled, randomized, double-blind clinical trial aimed to treat type 2 diabetes in Japan.

Reportedly, the Phase 3 study in Japan involved three crucial trials to assess Imeglimin’s safety and efficacy across 1,100 patients.

According to Prof. Hirotaka Watada, MD, PhD, Professor at Department of Metabolism & Endocrinology, Juntendo University, Tokyo, Imeglimin’s unique mechanism of action that focuses on very significant deficiencies occurring in diabetes combined with its safety profile, could massively improve the health of Japanese patients who earlier relied on insulin.

Source Credit: https://www.poxelpharma.com/en_us/news-media/press-releases/detail/128/poxel-announces-detailed-imeglimin-phase-3-times-1-results



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...